Change of concentration of biochemical markers of dysfunction of endothelium at intake of inhibitors of tyrosinekinase of I and II generations at patients with a chronic myeloid leukemia as risk factor of development of cardiovascular complications
Open Access
- 11 January 2021
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25, 4219
- https://doi.org/10.15829/1560-4071-2020-4219
Abstract
CML), the accepting inhibitors tyrosine of kinases (TKI) I and the II generations (TKI1 and TKI2 respectively), and development of arterial hypertension.Material and methods. Examination of 137 patients with CML in the chronic phase (CP) is conducted, the median of age — 47 years. 24 of them were with for the first time the verified diagnosis of CML and earlier did not accept TKI, they have made group of control. Other patients accepted TKI: 39 patients — imatinib 400 mg/day, 36 — dasatinib 100 mg/day, 38 — nilotinib 800 mg/day) more than 6 months. In biochemical analysis of blood indicators of lipidic range were defined. Level detection of ET-1 and VEGF was made by means of enzyme immunoassay. To all patients measurement of the heart rate (HR) and the arterial blood pressure (ABP) on both hands at an interval of 2 minutes from previous was once taken.Results. In group of patients from CML accepting nilotinib authentically significant increase in levels of systolic and diastolic ABP (рConclusion. As a result of the conducted research endothelium variation of a function at patients from CML accepting TKI1 and TKI2 is revealed. The above-stated indicators can be used as additional diagnostic criteria for assessment of risk of development of arterial hypertension in patients with CML at reception of TKI.Keywords
This publication has 22 references indexed in Scilit:
- Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological MalignanciesBone Marrow Research, 2016
- Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patientsHaematologica, 2015
- Homocysteine-Induced Endothelial DysfunctionAnnals of Nutrition and Metabolism, 2015
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyCancer, 2012
- Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of TreatmentJournal of Immunology Research, 2010
- Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemiaActa Pharmacologica Sinica, 2010
- Translation of the Philadelphia chromosome into therapy for CMLBlood, 2008
- The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient OutcomesJournal of the American College of Cardiology, 2006
- VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculatureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006